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Abstract
Therapies based on biologics involving delivery of proteins, DNA, and RNA are currently among 
the most promising approaches. However, although large combinatorial libraries of biologics and 
delivery vehicles can be readily synthesized, there are currently no means to rapidly characterize 
them in vivo using animal models. Here, we demonstrate high-throughput in vivo screening of 
biologics and delivery vehicles by automated delivery into target tissues of small vertebrates with 
developed organs. Individual zebrafish larvae are automatically oriented and immobilized within 
hydrogel droplets in an array format using a microfluidic system, and delivery vehicles are 
automatically microinjected to target organs with nearly perfect repeatability and precision. We 
screened a library of lipid-like delivery vehicles for their ability to facilitate the expression of 
protein-encoding RNAs in the central nervous system. We discovered delivery vehicles that are 
effective in both larval zebrafish and rats. Our results showed that the in vivo zebrafish model can 
be significantly more predictive of both false positives and false negatives in mammals than in 
vitro mammalian cell culture assays. Our screening results also suggest certain structure-activity 
relationship, which can potentially be applied to design novel delivery vehicles.
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Introduction
Biologics such as nucleic acids1,2, proteins3, cells4, and nanoparticle vehicles for drug 
delivery5 are currently under active investigation as therapeutics for a wide variety of human 
diseases. In contrast to chemically synthesized small molecules with enhanced solubility and 
permeability, these molecules have structures that are generally much larger and far more 
complex, and therefore require sophisticated modes of delivery6–9. Consequently, although 
large libraries of biologics and delivery vehicles are currently available10–13, it remains 
challenging to rapidly assess their in vivo properties such as delivery efficiency, 
biodistribution, pharmacokinetics, tissue specificity, efficacy, and toxicity.
Zebrafish (Danio rerio) are being increasingly used for large-scale in vivo chemical and 
genetic screens. A combination of features, including small size, optical transparency, and 
rapid organogenesis, make zebrafish a vertebrate model that is uniquely suited for high-
throughput screening (HTS)14–16, which is cost-prohibitive in mammals. HTS of small 
molecules in zebrafish not only enables detection of adverse toxicity and off-target side 
effects in the early stages of pharmaceutical development17, but has also led to the discovery 
of novel therapeutics currently undergoing clinical trials18. However, most biologics cannot 
be absorbed from the water due to their high molecular weight or unfavorable physical and 
chemical properties, and delivery of biologics into animals often requires manual 
microinjection19, a process that is too slow and labor-intensive for HTS. Although 
automated microinjection systems have been developed for delivery of nucleic acids into the 
large yolk cells of zebrafish embryos immediately after fertilization20, there is currently no 
high-throughput technology suitable for targeting specific organs of developed larvae and 
screening biologics in vivo, due to various technical challenges in different aspects of 
handling live larval zebrafish, including requirement of proper immobilization and 
orientation of larvae for micropipette to access different organs; difficulty to identify 
specific anatomic structures over transparent background; and lack of methods for parallel 
processing of multiple larvae. Thus, although zebrafish is an established model for study of 
human disease and also function of organs such as CNS, liver, kidney, and even blood brain 
barrier which are all relevant to delivery and processing of biologics, no study of biologics 
or delivery vehicle formulations have been reported using zebrafish.
To address this need, we have developed an automated system for efficient delivery of 
biologics into target organs of zebrafish larvae for high-throughput in vivo screening. The 
system utilizes a microfluidic component to automatically distribute zebrafish larvae into an 
array of hydrogel droplets, each containing a single larva. While the hydrogel is still in a 
liquid state, vibrational stimulation or mild anesthesia is used to induce the larvae to assume 
either a dorsal or a lateral orientation. Subsequently, the substrate temperature is lowered 
causing the droplets to solidify and restrict all further motion. Next, the microinjection 
needle is automatically targeted to organs of interest using an image template-matching 
algorithm, and biologics are injected via a pressure driven system. Phenotypic outcomes, 
including in vivo distribution of biologics and gene expression, are then examined by optical 
imaging. Using this system, we screened a library of lipid-like compounds for their ability to 
facilitate the delivery and expression of oligonucleotides (protein-encoding RNAs) in the 
central nervous system (CNS) following injection into the cerebrospinal fluid (CSF) of the 
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brain ventricles. Injection of biologics into CSF for therapeutics has been already used in 
clinical trials in neurodegenerative diseases21. Our screen discovered novel lipidoid 
formulations that facilitate efficient delivery of long RNA into CNS. We further showed that 
lipidoid activity in live rats is far better predicted by the in vivo zebrafish model than by a 
standard in vitro mammalian neural cell culture assay.
Results
High-throughput in vivo biologics delivery and screening
We developed an automated microinjection system for high-throughput delivery of biologics 
to target tissues of zebrafish larvae at 4 days post fertilization, a stage at which all major 
organs have formed (Fig. 1). Initially, zebrafish larvae are placed in a heated plate 
containing embryo medium supplemented with 1% ultra-low gelling temperature agarose. 
The agarose-based hydrogel remains in the liquid phase at room temperature (25°C) and 
solidifies when briefly lowered below 17°C and increased back to 25°C. Brief exposure to 
this temperature range does not affect health of larvae22, as we also verify below in 
assessment of our overall procedure’s effect on health. Zebrafish larva are acquired from the 
reservoir using a microfluidic component we developed, which incorporates a multi-color 
multi-angle light-scattering and photo-detection system to discriminate individual larvae 
from debris and bubbles and to guarantee successful acquisition of a single larva23, 24. Next, 
a hydrogel droplet containing the larva is deposited onto a flat plate using a computer 
controlled syringe pump and motorized X-Y stage (Movie S1). The plate surface is pre-
patterned with arrays of hydrophilic spots (96- or 48-well plate format) on a hydrophobic 
background, such that each hydrogel droplet remains confined within a precisely defined X-
Y location in order to prevent mix-up with neighboring droplets. The use of hydrophilic 
spots surrounded by hydrophobic background allows generation of densely packed isolated 
droplets. We use droplet volumes large enough to avoid drying out, narrow enough to fit the 
array dimensions, and shallow enough to minimize the height of each hydrogel droplet to 
avoid optical distortion (25 μL for 96-spot arrays and 70 μL for 48-spot arrays).
The plate with arrays of larvae in liquid hydrogel droplets is transferred to a motorized X-Y 
stage with a thermoelectrically temperature-controlled substrate. To image and microinject 
to different organs of zebrafish, the larvae are manipulated to adopt one of two major 
orientations. For injection into dorsal targets, larvae within the hydrogel are agitated with 
several pulses of mechanical vibrations, which trigger a startle response that causes them to 
assume a dorsal-up orientation. For injection into lateral and ventral targets, larvae are 
anesthetized by addition of 0.2 mg/mL tricaine to the hydrogel solution, causing most to 
settle into a lateral orientation. After being properly oriented, the hydrogel droplets are 
solidified by cooling to 4°C with a thermoelectric module, which results in effective 
immobilization of the larvae within droplets. For larvae at 4 days post-fertilization (dpf), the 
success rates for dorsal and lateral orientation are 93±7% and 84±3%, respectively (Table 1, 
n = 323). With these methods, different organs within a larva, including forebrain, midbrain, 
ventricles, eyes, heart and liver, can be successfully targeted for microinjection (Fig. 1b).
Using an in-house developed image recognition program (see Methods) and a high-speed 
camera, the system automatically locates each larva within a hydrogel-droplet, positions the 
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larvae to the center of field of view, and zooms in with motorized z-focus (Fig. 1a, Movie 
S2). Our algorithm identifies the eyes and the anterior-posterior axis of a larva, which can 
then be used as a reference coordinate to calculate the location of specific organs of interest. 
At the beginning of the microinjection process, the micropipette is front-loaded with 
biologics from a multiwell plate and then lowered to approach the target tissue/organ 
surface. By comparing of real-time the image of the larva’s exterior surface with the one 
from previous sampling point while the micropipette approaches the target organ, our 
algorithms detect the distortion of the exterior surface by the needle prior to the needle’s 
penetration into the larva. This allows our system to automatically not only identify the 
physical contact of the micropipette with the surface of the larva but also calculate its depth 
of penetration into the larva (see Methods, Movie S3). Subsequently, a pressure-driven 
picoliter-precision injector is triggered to deliver the biologics. The overall success rate of 
the automated microinjection into larval brain is 97% (n = 150). While the successful 
injection rate for other organs could be lower due to different properties, such as size, 
location, and movement etc., the hardware and algorithms could be further tuned according 
to specific applications. The average deviation of the automatically-targeted injection site 
from the desired site of injection (as determined by the user) is only 49 ± 3 μm (distance ± 
s.d., n = 75 from 3 separate experiments), allowing highly precise targeted delivery into 
specific organs. After microinjection, a self-adhesive bottomless multiwell chamber is 
attached onto the plate with arrays of larvae to isolate the hydrogel droplets from each other 
prior to a flushing process. The single-larva-containing hydrogel droplet in each well is then 
flushed with embryo medium to release the larvae from the droplets. It takes 20.0 ± 0.9 
seconds per larva on average to finish a complete cycle of loading, arraying, orientation, 
immobilization, target identification, microinjection, and recovery. This time can be further 
decreased to 13.1 ± 0.5 seconds per larva by pipelining the steps of arraying and injection 
(Table 2). This is considerably faster especially when compared to manual injection, which 
at least takes a trained technician several minutes19, 25 to perform all the necessary 
procedures including anesthesia, immobilization, orientation of a single larva, and injection 
to the target organ. This is also exceptionally fast in practice, as one can screen thousands of 
delivery vehicle formulations/biologics in one week alone, which would otherwise take 
months to years if performed manually.
To evaluate whether the health of zebrafish larvae is affected by our system, we assessed 
291 larvae using functional and morphological criteria (4 dpf) after passage through our 
system. Assessment of both survival and morphological abnormality (see methods) showed 
that our system caused no statistically significant adverse effects on zebrafish larvae with 
respect to controls (Fig. 2).
In vivo screening of lipidoids
Using our automated organ-targeted delivery system, we screened a combinatorial library of 
lipid-like compounds termed ‘lipidoids’ to identify vehicles capable of facilitating efficient 
in vivo delivery of biologics into CNS tissues. This lipidoid library was synthesized using 
epoxide conjugation and is composed of amino alcohols consisting of polar amine-
containing head groups and nonpolar hydrocarbon tails (lipidoids)6. We tested the entire 
library for in vivo delivery of protein-encoding RNAs to cells of the brain ventricle zone 
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following injection into the CSF of the ventricular cavity. Delivery of biologics into CSF has 
particular translational value as similar approaches have been already employed in clinical 
trials for therapeutics of neurodegenerative diseases21. In contrast to DNA-based gene 
therapy, RNA offers an alternative strategy for the administration of therapeutic proteins 
without the risk of cell transformation26, 27. However, successful in vivo delivery of protein-
coding RNAs has been a significant challenge due to their large size and susceptibility to 
enzymatic degradation7, 27, 28.
In order to quantify RNA delivery efficiency, lipidoids were complexed with RNA (25 pg) 
encoding the fluorescent reporter protein mCherry. RNA:lipidoid complexes were 
formulated at a 1:10 weight-to-weight ratio and microinjected into the brain ventricles of 
zebrafish larvae using our system. Expression of mCherry was examined 24 hours post-
injection by fluorescence imaging. Expression levels in the brain tissue were quantified by 
measuring the total mCherry fluorescence in each larva (n=10 per lipidoid). Our screen 
identified several lipidoids (such as C16-62) that significantly enhance in vivo delivery and 
expression of mCherry RNA in the CNS, and were far better than the tested commercially 
available products (Fig. 3).
Zebrafish are more predictive than cell culture of performance in rodents
To assess whether our screening results in zebrafish are predictive of outcomes in 
mammalian models, we selected the three most effective lipidoids (C16-62, C16-120, 
C12-120), and two low-scoring ones (C8-100 and C10-62) and tested them in vivo in rats. 
We injected mCherry RNA (0.1 μg) complexed with selected lipidoids into the lateral 
ventricles of adult rats using a stereotactic apparatus. Animals were allowed to recover for 
48 hours before they were sacrificed, and brain tissue slices were collected. The expression 
levels of mCherry in the slices were quantified using the overall fluorescence within 250 μm 
of the ventricle wall, a distance comparable in size to the zebrafish brain (Fig. 4a). We also 
investigated the ability of an in vitro model to predict delivery efficiencies of these lipidoids 
in rodents by testing the same group of lipidoids in rat primary hippocampal cultures. 48 
hours after seeding the cells, cultures were incubated in growth medium containing mCherry 
RNA complexed with lipidoids and then imaged to quantify the overall mCherry expression.
Interestingly, all lipidoids showed highly similar trends of in vivo RNA delivery efficiencies 
when tested in zebrafish or rodent animals. In both models, expression of mCherry was 
significantly increased above baseline in the presence of C16-62, C16-120, and C12-120, 
but not C8-100 or C10-62 (Fig. 4b). The active lipidoids showed clear differences in 
performance, with C16-62 performing significantly better than C12-120 in both in vivo 
models (p < 0.05 for zebrafish, and p < 0.01 for rat). These trends were observed by both 
dot-blotting of mCherry protein from isolated tissue (Fig. 4b) and quantitative fluorescence 
imaging of brain slices (Fig. 4c). The overall correlation in delivery efficiencies of the 
lipidoids tested in zebrafish and rodent animals was very high, with a Pearson product-
moment correlation coefficient of 0.97 (Fig. 4d). In contrast, the in vitro primary 
hippocampal culture model failed to identify C16-62, the most effective lipidoid in both rats 
and zebrafish (p> 0.18, Fig. 4c), and C16-120 was incorrectly predicted to be significantly 
more efficient than C16-62 (p < 0.02) by in vitro assay, although these compounds were not 
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statistically different in either zebrafish or rodents (p > 0.3 for zebrafish, and p > 0.1 for 
rodents). In general, unlike the zebrafish model, the in vitro cell culture assay failed to show 
any strong correlation with the in vivo results in rodents (correlation coefficient = 0.47, Fig. 
4d).
Discussion and Conclusion
Technologies for synthesizing biologics and specialized delivery vehicles have become 
increasingly sophisticated. However, large-scale assessment of their in vivo efficacy has 
remained challenging due to the lack of vertebrate animal models amenable to HTS. To 
address this significant need, we have developed an automatic organ-targeted microinjection 
system for screening biologics using zebrafish larvae. The system is based on a novel “fish-
array” design, which creates arrays of hydrogel droplets, each containing a single larva, for 
delivery of biologics. We have demonstrated the capability of our system by screening a 
library of lipidoid compounds for their ability to efficiently deliver protein-coding RNAs 
into CNS cells following microinjection into the CSF.
Expression of specific proteins within the brain by delivery of encoding nucleic acids is 
potentially of great therapeutic value for a variety of CNS diseases29. Efficient RNA 
delivery is of particular interest for clinical applications where transient protein expression is 
desirable. For example, expression of neurotrophic proteins has the potential to provide both 
pre-operative neuroportection30 and to serve as an effective therapy following CNS or spinal 
cord injury. Trans-differentiation of reactive astrocytes to neuronal progenitors by delivery 
of transcription factor mRNAs expressing Sox2 or GATA3 may be another route for CNS 
regeneration following trauma or degeneration31–33. The use of RNA offers significant 
advantages over DNA-based gene therapy approaches, which present a number of safety 
concerns27. The clinical utility of therapeutic RNAs has so far been limited due to the strong 
immunogenicity, limited stability, and difficult delivery of RNAs in vivo. In recent years, we 
and others have shown that the immunogenicity of exogenous RNA can be suppressed by 
transiently and locally silencing the innate immune response27, 34, 35. However, in vivo 
delivery of RNA to most tissues still remains an unsolved challenge. The technology we 
have developed makes it possible for the first time to rapidly test numerous vehicle 
formulations for their ability to deliver RNA in vivo. The delivery scheme we used (i.e. 
injection of lipidoid-RNA complexes into CSF) is of direct clinical relevance, as lumbar 
intrathecal injection is anticipated to be a minimally invasive means for nonviral delivery to 
the CNS, and biologics delivered to the CSF has been shown to diffuse and distribute 
throughout extended regions of CNS in both rodents and humans29, 36. Our discovery of 
several vehicle formulations (C16-62, C16-120, C12-120) that are highly efficacious in 
rodent models without false positives suggest that zebrafish can be used as a model for high-
throughput screening of biologics in vivo and, is more accurate than in vitro cell culture 
models in predicting outcomes in mammals. Interestingly, further analysis of our screening 
results also suggests certain structure-activity relationship, which can potentially be applied 
to design novel lipidoid delivery vehicles. The lipidoids are synthesized by conjugating 
amine-containing head groups and hydrocarbon tails6, 11. We found the length of 
hydrocarbon tails to be critical for the lipidoid’s RNA carrier/delivery capability in CNS. No 
compounds with hydrocarbon tails less than 12 carbons were effective, which is in line with 
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a previous report by Love et al11. For the amine head groups, amine 120 and 62 were in the 
top three most effective compounds (Fig. 3a). However, not all compounds based on amine 
120 or 62 showed enhanced RNA delivery, such as C10-62 and C10-120, both of which 
showed very little efficacy in our in vivo screen, further suggesting the importance of proper 
length of non-polar chains.
The reliability of the system depends on successful implementation of all operational 
procedures, including fish loading, immobilization/orientation, and microinjection. For 
example, we reported a success rate of ~93% or ~97% for dorsal orientation and ventricle 
injection, respectively. Given an almost 100% loading reliability, our system can perform 
brain injection with ~90% reliability. It can potentially be used to automate and scale-up a 
variety of in vivo assays. For instance, zebrafish larvae have been shown to be a promising 
model for studying the blood-brain barrier and intravenous injection using our platform 
could be used to screen for vehicles that facilitate delivery of biologics from the circulatory 
system to the CNS. In addition, a number of disease models require precise delivery of cells 
to specific organs or body cavities. For example, human tumor cells have been injected into 
zebrafish to generate xenograft tumor models37 and bacteria have been injected to model 
infection and pathogenesis38. Using manual microinjection to generate sufficient numbers of 
animals for large-scale chemical screens would be too laborious. Our system can be used for 
rapid implantation of cells on a scale that is compatible with HTS of chemical libraries to 
identify anti-tumorigenic or anti-infectious drug leads.
Methods and Materials
Surface treatment for generating fish-arrays
Transparent hydrophobic polystyrene plates were plasma-treated with the protection of a 
PDMS mask containing arrays of holes (48- or 96-well format) to create circular hydrophilic 
spots over a hydrophobic background. The diameters of the 48- and 96-well spots are 8 mm 
and 5 mm, respectively.
Image processing for automated microinjection
A coordinate system is established using the centroids of the both eyes, the swim bladder, 
and the axis of the trunk as landmarks. The eyes and swim bladder are identified based on 
their contrast with other larval surface features using a threshold-based segmentation 
algorithm. An image of the larva embedded in agarose is first captured by a high-speed CCD 
camera (GX-1050, Prosilica) through a Nikon AZ-100 Multizoom microscope and then 
converted to a binary image using a threshold, where the threshold value is determined via 
statistical analysis of the overall illumination level of the image. Next, the objects in the 
binary image are filtered to eliminate smaller high-contrast objects such as melanocytes, 
leaving only the eyes and swim bladder. The filtering is performed by removing pixel-
connected objects composed of pixels less than a threshold value. The threshold size is 
automatically adjusted to obtain only 3 objects from the images. Since the eyes are located 
closer to each other than they are to the swim bladder, the two objects with the least distance 
between their centroids are designated as eyes and the remaining object is recognized as the 
swim bladder. The anterior-posterior axis can be determined either by using curve-fitting 
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along the centroids of eyes and swim bladder or by rotation image-correlation with a 
reference image of larva. Automated injection is then performed by diagonally lowering the 
injection micropipette (Micromanipulator: Patchman NP2, Eppendorf; Injector: Xenoworks, 
Sutter Instrument) to approach the target while monitoring the difference between real-time 
images and the pre-injection images to detect the contact and penetration of the micropipette 
tip. Specifically, after the micropipette tip contacts the exterior of the larva, but before it 
actually penetrates any tissue, the difference between the real-time images and the pre-
injection images increases dramatically as the tissue is pressed by the tip and deforms. 
Following the penetration of the micropipette into the tissue, the image difference decreases 
as the tissue deformation relaxes. After penetration is detected, a 1 nL volume is injected by 
triggering a pressure drive picoliter microinjector (Sutter Instrument). Following injection, 
the micropipette is retracted to the home position. The automation control of microinjector 
and data readout is through NIDAQ cards (NI 9422; NI USB-6211). Software is developed 
on Matlab and can be provided by request.
Health assessment of larvae processed by the system
For health assessment and all subsequent experiments, the syringe pump was operated at 
aspiration rates of 330 μL/s. 4 dpf larvae were loaded from a reservoir, deposited onto the 
surface-treated plate, microinjected with 1 nL of PBS, and recovered for assessment by 
briefly flushing the surface of each hydrogel droplet with low-pressure stream of embryo 
medium. In total, 291 larvae were processed and compared with a control group of 187 
larvae from the same clutch. Health assessment was based on both functional and 
morphological criteria. Functional criteria included visual confirmation of normal heartbeat 
and reflex response to touch stimuli. Morphological criteria included spine bending (i.e. 
lordosis, kyphosis, and scoliosis) and craniofacial abnormalities39. Larvae were assessed 
immediately after recovery from the hydrogel droplets and again every 24 hours over the 
course of the next 4 days.
RNA synthesis
Templates for in vitro transcription were prepared as previously reported34. Briefly, the 
mCherry open reading frame, flanked by the human β-globin (HBB) 5′- and 3′-untranslated 
regions (UTRs), was cloned into the pCR-Blunt II-TOPO vector (Invitrogen). A strong 
Kozak consensus sequence was included between the 5′-UTR and the protein-coding 
sequence to promote efficient translation of the encoded protein. Templates were amplified 
using high-fidelity PCR (Kapa Biosystems) and in vitro synthesis of Cap 1-capped 
polyadenylated RNA was carried out using the mScript mRNA Production System 
(CELLSCRIPT, Inc.). Pseudouridine and 5-methylcytidine were substituted for uridine and 
cytidine in all in vitro transcribed RNAs. RNAs were purified using RNeasy Midi Kits 
(Qiagen) and the quality of the transcripts was assessed by denaturing agarose gel 
electrophoresis.
Lipidoid-RNA formulations
The lipidoids were dissolved in ethanol to make 50 mg/mL stock solutions. The stock 
solutions were sonicated for 5 minutes immediately before being diluted in PBS to 5 
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mg/mL. To formulate lipidoid-RNA complexes, 0.5 μg of mCherry RNA was mixed with 
lipidoids in PBS at a 1:10 weight ratio to make 20 μL working solutions. The lipidoid-RNA 
mixture was incubated for 15 minutes at room temperature prior to injection into animals or 
addition to cell culture medium.
Stereotactic injection to rats
Sprague-Dawley rats (<350 g) were purchased from Charles River Laboratory. Young adult 
female rats were dosed with buprenorphine and meloxicam two hours prior to isoflurane-
based anesthesia administration. The scalp was opened and retracted. An entry hole (~3 mm 
in diameter) for injections was made through the skull using a dental drill with burr bit. 
Injections were made into the lateral ventricle at stereotactic coordinates −3.0 RC −0.5 ML 
−15 DV mm using 10 μL Hamilton syringes. 4 μL of mCherry RNA-lipidoid complex was 
injected at a rate of 0.06 μL/s. Following injection, the skull was cemented and the scalp was 
sutured. Animals were given post-operative dosages of buprenorphine and meloxicam at 8 
hours following surgery and every 12 hours thereafter. 48 hours after injection, animals were 
sacrificed and brain tissue was immediately collected. 200 μm thick whole brain coronal 
slices were taken using a Vibratome (Leica), and either fixed and stained or immediately 
imaged. All animal work was carried out with prior approval of MIT’s Committee on 
Animal Care (CAC) and the Department of Comparative Medicine (DCM) and was in 
accordance with local, state, and federal animal care guidelines.
Dot blotting of rat brain tissues
A total 200 μg of tissue along the ventricle wall was dissected from each animal and kept 
frozen. Proteins were extracted from the tissues using a total protein extraction kit 
(Millipore). The proteins were analyzed through standard blotting procedures to semi-
quantitatively confirm the expression of mCherry in the brain ventricle region.
Assessment of in vitro delivery efficacy using primary rat primary hippocampal cultures
Primary cells were harvested from the hippocampi of E18 Sprague-Dawley rat pups 
obtained from Charles River Laboratories. Hippocampal tissue was digested using papain 
and mechanical trituration. Cells were plated onto poly-ornithine/laminin coated 24-well 
plates with a density of approximately 100,000 per well. Cells were cultured in medium 
composed of 50/50 DMEM/F12, 0.5× N2 and 0.5× B27 supplements. 1% Penicillin/
Streptomycin was added to the medium for the first 36 hours following harvest and 
subsequently removed 4 hours before transfection to avoid adverse effects on lipid-based 
delivery vehicles. Transfections were carried out by adding 20 μL of the lipidoid-RNA 
complex (containing a total of 0.5 μg RNA) to each well and incubating the primary 
hippocampal cultures at 37°C for 24 hours. After incubation, mCherry expression was 
observed via fluorescence imaging with 10X magnification, and the images were analyzed 
using Nikon Elements AR.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Chang et al. Page 9
Integr Biol (Camb). Author manuscript; available in PMC 2015 October 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Acknowledgments
All zebrafish used in these studies were raised and maintained in the Koch Institute Zebrafish Core Facility directed 
by Dr. Nancy Hopkins. We thank Dr. Adam Amsterdam for his oversight of the fish facility and Tim Angellini for 
technical assistance in raising and maintaining the fish. We thank the following funding sources: NIH 
Transformative Research Award (R01 NS073127), NIH Director’s Innovator award (DP2 OD002989), Packard 
award in Science and Engineering, Sanofi Pharmaceuticals, Foxconn Sponsorship and Hertz fellowship. P.S. is also 
supported by an early career award from UGC Hong Kong (125012), NSFC (81201164), ITC (ITS/376/13) and 
grants from City University of Hong Kong (9610215, 7200269).
References
1. Burnett JC, Rossi JJ. Chemistry & biology. 2012; 19:60–71. [PubMed: 22284355] 
2. Harms AS, Barnum CJ, Ruhn KA, Varghese S, Trevino I, Blesch A, Tansey MG. Molecular 
therapy : the journal of the American Society of Gene Therapy. 2011; 19:46–52. [PubMed: 
20959812] 
3. Stohl W, Hilbert DM. Nature biotechnology. 2012; 30:69–77.
4. Kim SU, de Vellis J. Journal of neuroscience research. 2009; 87:2183–2200. [PubMed: 19301431] 
5. Alexis F, Pridgen EM, Langer R, Farokhzad OC. Handbook of experimental pharmacology. 
2010:55–86. [PubMed: 20217526] 
6. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen 
DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, 
Narayanannair Jayaprakash K, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, 
Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DW, Soutschek J, Toudjarska I, Vornlocher HP, 
Zimmermann TS, Langer R, Anderson DG. Nature biotechnology. 2008; 26:561–569.
7. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Nature biotechnology. 2005; 
23:457–462.
8. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, 
Chu Q, Blokhin AV, Hagstrom JE, Wolff JA. Proceedings of the National Academy of Sciences of 
the United States of America. 2007; 104:12982–12987. [PubMed: 17652171] 
9. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, 
Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, 
Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, 
Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I. Nature. 2006; 441:111–114. 
[PubMed: 16565705] 
10. Falschlehner C, Steinbrink S, Erdmann G, Boutros M. Biotechnology journal. 2010; 5:368–376. 
[PubMed: 20349460] 
11. Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, Qin J, Cantley W, Qin 
LL, Racie T, Frank-Kamenetsky M, Yip KN, Alvarez R, Sah DW, de Fougerolles A, Fitzgerald K, 
Koteliansky V, Akinc A, Langer R, Anderson DG. Proceedings of the National Academy of 
Sciences of the United States of America. 2010; 107:1864–1869. [PubMed: 20080679] 
12. Yang X, Li N, Gorenstein DG. Expert opinion on drug discovery. 2011; 6:75–87. [PubMed: 
21359096] 
13. Shi P, Scott MA, Ghosh B, Wan D, Wissner-Gross Z, Mazitschek R, Haggarty SJ, Yanik MF. Nat 
Commun. 2011; 2:510. [PubMed: 22027590] 
14. Lieschke GJ, Currie PD. Nature reviews Genetics. 2007; 8:353–367.
15. Parng C, Seng WL, Semino C, McGrath P. Assay and drug development technologies. 2002; 1:41–
48. [PubMed: 15090155] 
16. Zon LI, Peterson RT. Nature reviews Drug discovery. 2005; 4:35–44.
17. Eimon PM, Rubinstein AL. Expert opinion on drug metabolism & toxicology. 2009; 5:393–401. 
[PubMed: 19368493] 
18. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber GJ, Bowman 
TV, Jang IH, Grosser T, Fitzgerald GA, Daley GQ, Orkin SH, Zon LI. Nature. 2007; 447:1007–
1011. [PubMed: 17581586] 
Chang et al. Page 10
Integr Biol (Camb). Author manuscript; available in PMC 2015 October 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
19. Gutzman JH, Sive H. Journal of visualized experiments : JoVE. 2009
20. Wang W, Liu X, Gelinas D, Ciruna B, Sun Y. PloS one. 2007; 2:e862. [PubMed: 17848993] 
21. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, Lozano AM, Penn RD, 
Simpson RK Jr, Stacy M, Wooten GF. Neurology. 2003; 60:69–73. [PubMed: 12525720] 
22. Long Y, Song G, Yan J, He X, Li Q, Cui Z. BMC Genomics. 2013; 14:612. [PubMed: 24024969] 
23. Chang TY, Pardo-Martin C, Allalou A, Wahlby C, Yanik MF. Lab on a chip. 2012; 12:711–716. 
[PubMed: 22159032] 
24. Pardo-Martin C, Chang TY, Koo BK, Gilleland CL, Wasserman SC, Yanik MF. Nature methods. 
2010; 7:634–636. [PubMed: 20639868] 
25. Cocchiaro JL, Rawls JF. Journal of visualized experiments : JoVE. 2013:e4434. [PubMed: 
23463135] 
26. Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE. Science. 1992; 255:996–998. 
[PubMed: 1546298] 
27. Kormann MS, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, Huppmann M, 
Mays LE, Illenyi M, Schams A, Griese M, Bittmann I, Handgretinger R, Hartl D, Rosenecker J, 
Rudolph C. Nature biotechnology. 2011; 29:154–157.
28. Vargason JM, Szittya G, Burgyan J, Hall TM. Cell. 2003; 115:799–811. [PubMed: 14697199] 
29. Leone P, Janson CG, Bilaniuk L, Wang Z, Sorgi F, Huang L, Matalon R, Kaul R, Zeng Z, Freese 
A, McPhee SW, Mee E, During MJ. Ann Neurol. 2000; 48:27–38. [PubMed: 10894213] 
30. Cao YJ, Shibata T, Rainov NG. Gene therapy. 2002; 9:415–419. [PubMed: 11960318] 
31. Blum R, Heinrich C, Sanchez R, Lepier A, Gundelfinger ED, Berninger B, Gotz M. Cereb Cortex. 
2011; 21:413–424. [PubMed: 20562320] 
32. Kizil C, Kyritsis N, Dudczig S, Kroehne V, Freudenreich D, Kaslin J, Brand M. Dev Cell. 2012; 
23:1230–1237. [PubMed: 23168169] 
33. Robel S, Berninger B, Gotz M. Nat Rev Neurosci. 2011; 12:88–104. [PubMed: 21248788] 
34. Angel M, Yanik MF. PloS one. 2010; 5:e11756. [PubMed: 20668695] 
35. Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Molecular therapy : 
the journal of the American Society of Gene Therapy. 2008; 16:1833–1840. [PubMed: 18797453] 
36. Anderson DM, Hall LL, Ayyalapu AR, Irion VR, Nantz MH, Hecker JG. Hum Gene Ther. 2003; 
14:191–202. [PubMed: 12639300] 
37. Taylor AM, Zon LI. Zebrafish. 2009; 6:339–346. [PubMed: 20047467] 
38. Takaki K, Cosma CL, Troll MA, Ramakrishnan L. Cell Rep. 2012; 2:175–184. [PubMed: 
22840407] 
39. Blechinger SR, Warren JT Jr, Kuwada JY, Krone PH. Environ Health Perspect. 2002; 110:1041–
1046. [PubMed: 12361930] 
Chang et al. Page 11
Integr Biol (Camb). Author manuscript; available in PMC 2015 October 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
The fish-array based automatic organ-targeted microinjection system. (a) Setup of the 
system. Larvae in liquid phase of ultra-low gelling temperature agarose hydrogel are 
automatically loaded from a reservoir into the system with a microfluidic component, and 
arrayed onto a surface-treated plate as single-larva-containing hydrogel droplets. Both the 
loading reservoir and arraying plates are placed on motorized X-Y stages, and the loading 
and dispensing nozzles are mounted on motorized Z stages. Depending on the desired 
orientation, the larvae are either agitated with a vibrating motor attached to the plate (for 
dorsal-up orientation) or anesthetized prior to loading (for them to orient laterally). Larvae 
are immobilized by cooling with a thermoelectric cooler to rapidly solidify the hydrogel 
droplets. The system automatically identifies each larva, positions the targeted region under 
the injection micropipette, and detects the contact and penetration of the tip of the 
micropipette. A computer-controlled pressure driven microinjector is then triggered to inject 
test compounds into the target organ. After injection, a self-adhesive bottomless multiwell 
chamber is attached to the plate and the larvae are recovered from the hydrogel by gently 
flushing each droplet with embryo medium. (b) Images of zebrafish larvae following 
automatic microinjection of FITC-coupled dextran molecules into different organs using the 
system.
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Figure 2. 
Health assessment of larvae after operations. (a) Survival rate of larvae following 
autonomous microinjection (red bars; n = 291) compared to control larvae from the same 
clutch (blue bars; n=187). (b) Percentage of larvae exhibiting morphological abnormalities 
following operations (red bars; n = 291) compared to control larvae from the same clutch 
(blue bars; n=187).
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Figure 3. 
In vivo high-throughput screening of a lipidoid library in larval zebrafish. a) The structure of 
a sample lipidoid material. b) Screening of vehicles for delivering RNA into CNS. RNA 
encoding full-length mCherry fluorescent protein was complexed with lipidoids and 
microinjected into the brain ventricles of 4 dpf larvae (n = 10 larvae per lipidoid compound). 
Insets of fluorescence images show expression of mCherry in brain tissue of the larva. The 
in vivo RNA delivery efficiency of all lipidoids was determined by quantifying total 
mCherry fluorescence intensity within the brain region of each larva. Red arrows indicate 
lipidoid compounds that were selected for further tests in rodents and primary hippocampal 
cultures.
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Figure 4. 
Comparison of lipidoid-mediated RNA transfection efficiencies in different models. (a) 
Images of a coronal rat brain slice near the injection site, scale bar = 5 mm. Lipidoids 
complexed with RNA were stereotaxically injected into the brain ventricles of adult SD rats. 
The black dashed box indicates the region used for quantification of mCherry protein 
expression. Fluorescence images show mCherry expression in the brain ventricle of rats 
injected with RNA alone, or with RNA complexed with lipidoid compounds, C16-120 and 
C16-62. Scale bars = 100 μm. (b) Image of Dot-blot showing mCherry protein expression 
levels in the rat brain tissues. (c) Quantification of lipidoid-mediated expression of mCherry 
in three different testing models, primary hippocampal cultures (red), zebrafish larvae 
(green) and rodent animal (blue), after delivering of lipidoid complexed RNA. Asterisks 
indicate significant differences with respect to RNA alone controls (* p < 0.05, ** p < 0.01; 
t-test, single-tailed). (d) Correlation between results from different testing models: rats vs. 
zebrafish (red), and rats vs. primary hippocampal culture (blue). The delivery efficiencies of 
tested lipidoid compounds from rodent models correlate well with the in vivo zebrafish 
model but not with results from in vitro primary hippocampal cultures. Expression levels in 
(c) and (d) are normalized with respect to control conditions.
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Table 1
Performance of the orientation mechanisms.
Orientation mechanism Success rate* (%)
Dorsal orientation by stimulation 93.4 ± 2.9
Lateral orientation by anesthetization 13.6 ± 6.6
Dorsal orientation without stimulation 60.0 ± 3.2
*
n = 323
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Table 2
Timeline of the autonomous microinjection operations.
Processing Step Time ± s.d.* (sec/larva)
Loading and arraying 13.1 ± 0.5
Positioning 1.0 ± 0.2
Injecting 5.1 ± 0.1
Orientation and immobilization in 96-well format 0.8 ± 0.1
Overall duration for each larva in series 20.0 ± 0.9
Overall duration for each larva after pipelining 13.1 ± 0.5
Test samples front-loading 19.9 ± 6.9
*
n = 60 for each
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